Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. (Q39118471)
Jump to navigation
Jump to search
scientific article published on 2 December 2016
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. |
scientific article published on 2 December 2016 |
Statements
Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study (English)
Matthew D Hellmann
Naiyer A Rizvi
Jonathan W Goldman
Scott N Gettinger
Julie R Brahmer
Neal E Ready
Laura Q Chow
Rosalyn A Juergens
Frances A Shepherd
Scott A Laurie
William J Geese
Shruti Agrawal
Tina C Young
Xuemei Li